本帖最后由 老马 于 2012-1-13 21:20 编辑 / @0 s2 I: l' |2 U6 a* L
; g# G" A0 c0 O B爱必妥和阿瓦斯丁的比较
$ ^, N c! }2 x' g% u- z5 U5 R. m
: m* H* s1 x1 e9 X/ z$ h5 n' q% Fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
4 o- y5 G' n4 u; o5 ]7 I5 M
/ y3 v; i8 |" q0 K
: j# H5 L8 Z( y* q% j* x% u
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' B! t" G; n( v$ J& k( j- u
==================================================$ m2 R' }# R- v* D0 T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
I: d Y0 }+ W) [3 x6 i3 ?3 nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ j% u% @+ X7 U5 k" _, QResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 Y0 ~3 S7 J( a% i/ R* X
|
显身卡
3 K8 M! @: Y8 ~/ t, }. ~
